Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Saavedra

Showing results (141-150 of 209) with videos related to

Pageof 21
Sort By:
Molecular Pharmacology|July 17, 2001
Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenicJ Liu, H Chen, D S Miller, et al.
The Journal of Pharmacy and Pharmacology|August 21, 2010
JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivoTanyel Kiziltepe, Kenneth C Anderson, Jeffery L Kutok, et al.
European Journal of Biochemistry|July 8, 1998
Sulfhydryl reagent susceptibility in proteins with high sequence similarity--triosephosphate isomerase from Trypanosoma brucei, Trypanosoma cruzi and Leishmania mexicanaG Garza-Ramos, N Cabrera, E Saavedra-Lira, et al.
Nitric Oxide : Biology and Chemistry|October 27, 2005
Deamidation of peptides in aerobic nitric oxide solution by a nitrosative pathwayLi Kong, Joseph E Saavedra, Gregory S Buzard, et al.
Genomics|April 8, 2009
Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cellsJie Liu, Swati Malavya, Xueqian Wang, et al.
Redox Biology|September 12, 2013
Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balanceAnna E Maciag, Ryan J Holland, Y-S Robert Cheng, et al.
Cell Death Discovery|March 3, 2017
ATF3 reduces migration capacity by regulation of matrix metalloproteinases via NF<i>κ</i>B and STAT3 inhibition in glioblastomaJessica Guenzle, Louisa J Wolf, Nicklas W C Garrelfs, et al.
Neurosurgery|August 19, 2011
JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomasAstrid Weyerbrock, Nadja Osterberg, Nikolaos Psarras, et al.
Journal of Cardiovascular Pharmacology|July 11, 2001
Analysis of vasodilator responses to novel nitric oxide donors in the hindquarters vascular bed of the catT J Bivalacqua, H C Champion, B J De Witt, et al.
Molecular Pharmaceutics|December 17, 2009
Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticlesVarun Kumar, Sam Y Hong, Anna E Maciag, et al.
Pageof 21

Showing results (141-150 of 209) with videos related to

Sort By:
Pageof 21
Molecular Pharmacology|July 17, 2001
Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenicJ Liu, H Chen, D S Miller, et al.
The Journal of Pharmacy and Pharmacology|August 21, 2010
JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivoTanyel Kiziltepe, Kenneth C Anderson, Jeffery L Kutok, et al.
European Journal of Biochemistry|July 8, 1998
Sulfhydryl reagent susceptibility in proteins with high sequence similarity--triosephosphate isomerase from Trypanosoma brucei, Trypanosoma cruzi and Leishmania mexicanaG Garza-Ramos, N Cabrera, E Saavedra-Lira, et al.
Nitric Oxide : Biology and Chemistry|October 27, 2005
Deamidation of peptides in aerobic nitric oxide solution by a nitrosative pathwayLi Kong, Joseph E Saavedra, Gregory S Buzard, et al.
Genomics|April 8, 2009
Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cellsJie Liu, Swati Malavya, Xueqian Wang, et al.
Redox Biology|September 12, 2013
Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balanceAnna E Maciag, Ryan J Holland, Y-S Robert Cheng, et al.
Cell Death Discovery|March 3, 2017
ATF3 reduces migration capacity by regulation of matrix metalloproteinases via NF<i>κ</i>B and STAT3 inhibition in glioblastomaJessica Guenzle, Louisa J Wolf, Nicklas W C Garrelfs, et al.
Neurosurgery|August 19, 2011
JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomasAstrid Weyerbrock, Nadja Osterberg, Nikolaos Psarras, et al.
Journal of Cardiovascular Pharmacology|July 11, 2001
Analysis of vasodilator responses to novel nitric oxide donors in the hindquarters vascular bed of the catT J Bivalacqua, H C Champion, B J De Witt, et al.
Molecular Pharmaceutics|December 17, 2009
Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticlesVarun Kumar, Sam Y Hong, Anna E Maciag, et al.
Pageof 21